Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
terbinafine / florfenicol / betamethasone acetate
Elanco Europe Ltd
QS02CA90
terbinafine / florfenicol / betamethasone acetate
Dogs
Otologicals-corticosteroids and antiinfectives in combination
Treatment of acute otitis externa
Authorised
2014-07-31
B. PACKAGE LEAFLET 14 PACKAGE LEAFLET: OSURNIA EAR GEL FOR DOGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: Elanco Europe Ltd., Lilly House, Priestley Road, Basingstoke, RG24 9NL, UNITED KINGDOM Manufacturer responsible for batch release : Argenta Dundee Limited, Kinnoull Road, Dunsinane Industrial Estate, Dundee DD2 3XR, UNITED KINGDOM 2. NAME OF THE VETERINARY MEDICINAL PRODUCT OSURNIA ear gel for dogs Terbinafine/florfenicol/betamethasone acetate 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One tube (1.2 g) contains 10 mg terbinafine, 10 mg florfenicol and 1 mg betamethasone acetate Excipient: 1 mg butylhydroxytoluene (E 321) Off-white to slightly yellow translucent gel. 4. INDICATION(S) For the treatment of acute otitis externa, and acute exacerbation of recurrent otitis externa associated with _Staphylococcus pseudintermedius_ and _Malassezia pachydermatis_ . _ _ 5. CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substances, to other corticosteroids, or to any of the excipients. Do not use if the eardrum is perforated. Do not use in dogs with generalised demodicosis (demodectic mange). Do not use in pregnant or breeding animals. 6. ADVERSE REACTIONS Post authorisation experience indicates that very rare cases of deafness or impaired hearing, usually temporary, in dogs have been reported after use, mainly in elderly animals. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 15 If you notice any side effects, even those not alre Przeczytaj cały dokument
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OSURNIA ear gel for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ ACTIVE SUBSTANCES: 1 dose (1.2 g) contains: Terbinafine: 10 mg Florfenicol: 10 mg Betamethasone acetate: 1 mg equivalent to Betamethasone base 0.9 mg EXCIPIENT: Butylhydroxytoluene (E321): 1 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Ear gel. Off-white to slightly yellow translucent gel. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs _ _ 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of acute otitis externa and acute exacerbation of recurrent otitis externa associated with _Staphylococcus pseudintermedius_ and _Malassezia pachydermatis_ . 4.3 CONTRAINDICATIONS Do not use in cases of hypersensitivity to the active substances, to other corticosteroids or to any of the excipients. Do not use if the eardrum is perforated. Do not use in dogs with generalised demodicosis. Do not use in pregnant or breeding animals. 4.4. SPECIAL WARNINGS FOR EACH TARGET SPECIES Clean the ears before the initial treatment is applied. Ear cleaning should not be repeated until 21 days after the second administration. In clinical trials, saline only was used for ear cleaning. Transient wetness of the inner and outer pinna can be observed. This observation is attributed to presence of product and is not of clinical concern. Bacterial and fungal otitis is often secondary to other conditions. Appropriate diagnosis should be used and therapy of causative conditions should be investigated before antimicrobial treatment is considered. 2 In animals with a history of chronic or recurrent otitis externa, efficacy of the product may be affected if the underlying causes of the condition such as allergy or anatomical conformation of the ear are not addressed. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals If hypersensitivity to any of the components occurs, the ear should be thoroughly washed. The safety of the product Przeczytaj cały dokument